CSCO Antily Lymphoma Alliance and Anti-Leukemia Alliance. The Youth Lymphoma Forum has come to a successful conclusion!

Isolation of virus, not isolation of academic; standardized diagnosis and treatment, a long way to go.from 14:00 to 17:25, July 6, 2020, sponsored by CSCO anti lymphoma Alliance & amp; anti leukemia alliance, China Association of medical education, and hosted by Harbin Institute of Hematology and oncology, the youth lymphoma forum of CSCO anti lymphoma Alliance & amp; anti leukemia alliance was officially opened.communicate with you in the form of expert online lectures and discussions.22 authoritative experts and young and middle-aged lymphoma experts from many places in China gathered in the live room to discuss the diagnosis and treatment standards, treatment progress and experience sharing of lymphoma.Professor Ma Jun of Harbin Institute of Hematology and oncology was invited as the chairman of the meeting, Professor Liu Weiping of Cancer Hospital of Peking University and Professor Zhao Donglu of Harbin Institute of Hematology and oncology were invited as the chairman of the executive meeting.invited speakers include Professor Zou Dehui, blood disease hospital, Institute of Hematology, Chinese Academy of Medical Sciences; Professor Li Zhiming, cancer prevention and treatment center, Sun Yat sen University; Professor Xu pengpeng, Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University; and Professor Zhao Donglu, Harbin Institute of Hematology and oncology.the opening ceremony of the conference was delivered by Professor Ma Jun.Professor Ma Jun first expressed his gratitude to all colleagues in the country for their efforts during the outbreak of Xinguan epidemic, and warmly welcomed the medical colleagues and young and middle-aged doctors who participated in the meeting online. During the epidemic period, CSCO anti lymphoma Alliance & amp; anti leukemia alliance provided a free academic exchange platform for young professionals in China, which was very gratifying."young people build dreams and have the courage to take responsibility". The young and middle-aged experts forum will continue to help young and middle-aged scholars broaden their research ideas, promote the standardization of lymphoma diagnosis and treatment, improve their professional quality, and promote the progress of lymphoma diagnosis and treatment.at the same time, Professor Ma wishes this forum a complete success.topic 1: progress in car-t cell therapy: Professor Zou Dehui, hematology hospital, Institute of Hematology, Chinese Academy of Medical Sciences, delivered a keynote speech and clinical practice and sharing on car-t cell therapy for refractory / relapsed non Hodgkin's lymphoma (NHL).Professor Zou made a comprehensive and detailed exposition on car structure, car-t cell therapy drugs, foreign clinical research, real world research, domestic car-t clinical research, and then to the clinical research of car-t treatment for invasive B-cell lymphoma in our center.finally, Professor Zou concluded that car-t cells targeting CD19 have shown great success in treating NHL, but the treatment is still in the early stage of development.in the future, we need to develop more car target antigens and other cell surface markers for the treatment of NHL, such as targeting CD5 and CD7 to treat T-NHL.based on the success of car-t targeting CD19, more clinical trials should be carried out to evaluate the efficacy of other car-t cell products (except CD19), reduce the cost, reduce the preparation time of patient specific car-t cell products, and reduce the incidence and severity of SAE, so as to further improve the efficacy of car-t cells in the treatment of NHL.the migration of treatment opportunity is under clinical trial.under the chairmanship of Professor Zhang Huilai and Professor Jin Fengyan, Professor Zou, together with the discussion guests Professor Huang Wenrong, Professor Liao Aijun and online experts in the field of car-t cell therapy, discussed the related factors of clinical remission and recurrence, the treatment of adverse reactions, the application of central involved patients, the treatment of invasive lymphoma, and the application of MRD patients Discussion on entering the land.topic 2: new progress of diffuse large B-cell lymphoma, Professor Li Zhiming, cancer prevention and treatment center of Sun Yat sen University, presented the keynote speech of "new progress of diffuse large B-cell lymphoma (DLBCL)".Professor Li elaborated on the new subtypes of DLBCL, pathological diagnosis, progress of initial treatment of DLBCL, and when to carry out central prevention in elderly or frail patients who are not suitable for R-CHOP and patients with high risk of CNS recurrence.finally, Professor Li concluded that R-CHOP is still the standard first-line treatment for DLBCL; single drug efficacy of small molecule targeted drugs is limited, and more patients will try combination scheme in the future; ADC drugs oncastuximab tessine or polatuzumab, targeting CD19, single antibody tafasitamab and double antibody glofitamab are in the R / R Car-t therapy plays an important role in the treatment of DLBCL, but it still needs to be improved and matured.under the chairmanship of Professor Bai ou and Professor Zhou Hui, Professor Li discussed with the guests Professor Sun Xiuhua, Professor Wang Huihan and online domain experts on why gemcitabine in diffuse large B cell lymphoma is inconsistent with that of solid tumor, the application and efficacy evaluation of pdg-pet-ct, and the precautions for immunotherapy of relapsed / refractory diffuse large B-cell lymphoma How to detect the expression of PD-L1 in B-cell lymphoma is discussed.topic 3: progress of T-cell lymphoma Professor Xu pengpeng, Ruijin Hospital Affiliated to Shanghai Jiaotong University Medical College, presented a keynote speech on "progress in diagnosis and treatment of peripheral T-cell lymphoma (PTCL): integration of molecular heterogeneity and clinical diagnosis and treatment".Professor Xu first summarized the epidemiology, disease characteristics, clinical and pathological classification, and prognosis stratification of PTCL, and then combined with the experience of Ruijin Hospital, made a comprehensive and detailed exposition from clinical treatment to individualized treatment.finally, Professor Xu concluded that he hoped to discover the molecular mechanism of disease from the research center, conduct transformation research, judge the prognosis of patients through molecular typing, select targeted drugs based on molecular markers, and then engage in fine research, so as to realize MICM diagnosis of PTCL.at the same time, we hope to cooperate with multi centers to carry out clinical targeted therapy research, such as chop / chop in low-risk patients, Cr combined with hematopoietic stem cell transplantation in high-risk patients, and chemotherapy regimen / combined with targeted drugs to achieve precise treatment of PTCL.under the chairmanship of Prof. Bao Huizheng and Prof. Gong Tiejun, Professor Xu discussed with the guests Professor Cai Qingqing and Professor Zhao Shu on how to select the corresponding drug treatment scheme from the gene aspect and the treatment suggestions for patients with TP53 mutation in three subtypes of peripheral T-cell lymphoma: non-specific, angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma The experience of immunotherapy, cell lines and animal models were extensively and actively discussed.topic 4: new progress of EHA chronic lymphoblastic leukemia (CLL) in 2020, Professor Zhao Donglu of Harbin Institute of Hematology and oncology presented the keynote speech of "2020 EHA CLL new progress".Professor Zhao first reviewed the previous treatment and the treatment recommendations of CLL in 2019, as well as the existing problems in CLL treatment.the latest research report of EHA 2020 is presented, which elaborates the preliminary results of s158 captivate study, s155 cll14 study, S160 icll-07 Filo study, S157 cll2-give study, MRD driven zebitinib, obinutuzumab and venetoclax initiated by a multi center researcher in China.finally, Professor Zhao concluded that the treatment of CLL is undergoing changes, and the combination of new drugs has achieved very high effective rate and negative MRD rate. The long-term efficacy is worth looking forward to, and the adverse reactions need to be paid attention to.under the chairmanship of Professor Zhang Chun and Professor Liu Gang, the guest of discussion, Professor Wang Xiaobo, agreed with Professor Zhao very much. The treatment of CLL has changed, and we should pay attention to its safety while accepting new drug treatment.Professor Zhao discussed with the guest of discussion Professor Zeng Dongfeng on the treatment of Richter syndrome, and Professor Zhao suggested that the treatment of diffuse large B-cell lymphoma should be referred to.at the end of the meeting, the chairman of the executive meeting, Professor Liu Weiping and Professor Zhao Donglu, made concluding remarks on the meeting. at the same time, the two executive presidents once again expressed their thanks to all the participants for their strong support. thanks to CSCO anti lymphoma Alliance & amp; young and middle-aged lymphoma forum for providing a professional academic exchange platform for young and middle-aged lymphoma clinicians in China. it promotes the standardization and innovation of lymphoma diagnosis and treatment. I believe that with the joint efforts of all of you, we can promote the level of lymphoma diagnosis and treatment in China, and benefit more patients. the youth lymphoma forum of CSCO anti lymphoma Alliance & amp; anti leukemia alliance was successfully concluded. stamp "read the original text", and let's make progress together